Renatus is a pharmaceutical company committed to providing safe and effective treatment options for various diseases caused by dysregulated cholesterol metabolism, including chronic kidney disease, atherosclerosis, and Alzheimer's disease.

 

The core technology of Renatus allows normalization of cholesterol homeostasis by removal of excessive and toxic cholesterol within diseased cells without significant harmful effects on normal cells.

​​

"I believe that cholesterol metabolism is a very promising therapeutic target in numerous diseases and Renatus is demonstrating this. Our goal is to translate the scientific discoveries into new drugs that can significantly improve the quality of lives of patients suffering from cholesterol-driven diseases."

 

- Dr. Heegon Kim, CEO of Renatus